Amicus Therapeutics (NASDAQ:FOLD) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research report sent to investors on Thursday,Benzinga reports.

Several other equities research analysts have also recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Guggenheim upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Stock Performance

NASDAQ FOLD opened at $9.07 on Thursday. The stock has a market capitalization of $2.71 billion, a PE ratio of -26.68, a P/E/G ratio of 1.65 and a beta of 0.61. Amicus Therapeutics has a 1-year low of $8.78 and a 1-year high of $14.02. The business has a 50 day simple moving average of $9.56 and a two-hundred day simple moving average of $10.41. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Large investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in shares of Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after purchasing an additional 4,497,950 shares during the period. Vestal Point Capital LP bought a new stake in Amicus Therapeutics during the 4th quarter valued at about $31,557,000. Norges Bank purchased a new stake in Amicus Therapeutics in the 4th quarter valued at about $29,033,000. Orbimed Advisors LLC boosted its position in Amicus Therapeutics by 300.7% in the 4th quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company’s stock valued at $21,528,000 after buying an additional 1,715,100 shares during the period. Finally, Rock Springs Capital Management LP grew its stake in Amicus Therapeutics by 107.9% in the 4th quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company’s stock worth $24,487,000 after acquiring an additional 1,349,145 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.